DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Vanda Pharmaceuticals Inc. Of Upcoming Deadline

Rigrodsky & Long, P.A.:
  • Do you, or did you, own shares of Vanda Pharmaceuticals Inc. (NASDAQ GM: VNDA )?
  • Did you purchase your shares before December 18, 2012, or between December 18, 2012 and June 18, 2013?
  • Did you lose money in your investment in Vanda Pharmaceuticals Inc.?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ GM: VNDA) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

A complaint was filed in the United States District Court for the District of Columbia on behalf of all persons or entities that purchased the common stock of Vanda between December 18, 2012 and June 18, 2013, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”). If you wish to serve as lead plaintiff, you must move the Court no later than August 26, 2013.

If you purchased shares of Vanda during the Class Period, or purchased shares prior to the Class Period and still hold Vanda, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to info@rigrodskylong.com, or at: http://www.rigrodskylong.com/investigations/vanda-pharmaceuticals-inc-vnda.

A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

If you liked this article you might like

Summit Therapeutics Stock Gets Smoked After IPO Pricing

Vanda Pharma (VNDA) Stock Price Target Upped on Drug Patent Ruling

Vanda Pharmaceuticals (VNDA) Stock Soars on Drug Patent Ruling

Strong On High Relative Volume: Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA) Flagged As Strong On High Volume